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Abstract
Background: Human immunodeficiency virus type 1 (HIV-1) induces a general dysregulation of immune system.
Dysregulation of B cell compartment is generally thought to be induced by HIV-related immune activation and
lymphopenia. However, a direct influence of HIV-1 particles on B cells was recently proposed as the third pathway of B cells
dysregulation.
Methods/Principal Findings: We evaluated the direct and specific consequences of HIV-1 contact on activation, survival,
proliferation and phenotype of primary B cells in vitro. Moreover, we examined expression of activation-induced cytidine
deaminase (AID) mRNA that is responsible for class switch recombination (CSR) and somatic hypermutation (SHM). Here, we
report that changes observed in cellular proliferation, phenotypes and activation of B cells could be caused by direct
contact between HIV-1 particles and primary B cells in vitro. Finally, direct HIV-1-derived B cells activation led to the increase
of AID mRNA expression and its subsequent CSR function was detected in vitro.
Conclusion/Significance: We showed that HIV-1 could directly induce primary B cells dysregulation triggering phenotypical
and functional abilities of B cells in vitro that could explain in some extent early B-cell abnormalities in HIV disease.
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Introduction
B cells are a critical component of the adaptive immune
system, by producing highly specific antibodies and by establish-
ing a CD27+ memory B cells. They are providing a specific and
a long-term protection from an extensive range of pathogens
[1,2]. During HIV infection and in humoral immunity context,
initial observations revealed that patients with acquired immune
deficiency syndrome (AIDS) could exhibit hyperimmunoglobuli-
nemia, increasing expression of cell-activation markers, depletion
of memory B cells inducing ineffective recall responses,
polyclonal B-cell hyperactivity, and altered differentiation of
naı¨ve B cells that could result in impaired immunoglobulin class
switch recombination (CSR), and thus production of nonspecific
immunoglobulin (Ig)G, IgE and IgA antibodies [3,4,5,6,7,8]. All
of these processes finally provoke defective responses to
opportunistic pathogens and vaccines [7,9]. The final step of
this general B cells dysregulation could be the exhaustion of B
cells compartment [10]. In general, HIV-1-related humoral
defects are thought to originate from general immune activation
and from the progressive CD4+ T cells lymphopenia since
optimal and specific B cell activation needs B and T cells contact
[11,12,13]. Until now, restoration of CD4+ T cells by antiret-
roviral therapy has not fully re-established antigen-specific IgG,
IgE and IgA responses and memory B cells [14,15,16,17], which
suggests an additional B cells dysregulation pathway. Consistent
with that possibility, few articles have shown that some viral
proteins could be directly implicated in B cells dysfunction
through gp120:DC-SIGN interactions, HIV-1 Nef delivered to B
cells via infected macrophages, through mannose C-type lectin
receptors or through CD21 [18,19,20,21,22,23]. Moreover,
complement receptor CD21 could not only bind HIV-1 in vitro
and in vivo but could as well facilitate CD4+ T cells infection
since B cells-associated HIV-1 is far more infectious for T cells
than is free virus [22,24,25]. In consequence, and without
evidence of direct infection, B cells could directly be dysregulated
by HIV-1, if cells transport HIV-1 particles attached at their
surface. How HIV-1 permits to dysregulate indirectly or directly
B-cell in vivo, it is not still well defined albeit incorporation of
CD40L into virion membrane during HIV budding could be one
the B-cell activation process [26,27,28]. In fact, it is not
completely clear if only CD40L-associated with HIV-1 or other
human or viral compounds could be involved in general B cells
dysregulation and thus helping the HIV-1 spreading in patients.
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In this study, we first confirmed the rapid phenotype
dysregulation and activation of peripheral primary B cells after
direct HIV-1 contact. We then examined the survival rate of HIV-
associated B cells when cultured in vitro. Interestingly, human
primary B cells survival rate and cellular proliferation were
increased when B cells were put in contact with HIV-1. Moreover,
expression level of AID mRNA in human primary B cells was
highly increased and its subsequent IgM/IgE; IgM/IgA and IgM/
IgG class switch was detected in vitro. These results may highlight a
possible relation between HIV-1 infection and B cells hyperactiva-
tion, loss of memory B cells or hyperglobulinemia.
Results
B Cells Survival in vitro
After B cells isolation from PBMC of healthy volunteers, B cells
were cultured in vitro in culture medium with or without stimulant
factors. Percentages of living cells were followed by 7-AAD labeling
by flow cytometry [29]. As expected the half-life of non-treated B
cells culture was rather short. Surprisingly, after 6 days of treatment
B cells survival was better when cells were treated with HIV-1, with
CD40L/IL-4 or with LPS/IL-4 where an average of 40–60% of
living B cells in comparison with boiled HIV-1 condition (corre-
sponding to denaturedHIV-1-derived antigens) or with non-treated
cells (Figure 1A) as NT condition at day 1 corresponded to 100% of
B-cell survival. We produced HIV-1 into cells MT2 that did not
contain CD40L, confirmed by flow cytometry (Figure S1).
Therefore, the HIV-1 produced was free of CD40L at their surface.
Thus, a better B cells survival related to HIV-1 was not due to the
presence of CD40L at the surface of virions.
To know if this survival rate was due to a resistance to apoptosis
or to proliferation, we had submitted B cells to a CFSE pre-
treatment before cultivating them. Proliferation was followed by
the loss of CFSE signal by flow cytometry (Figure S2). Proliferation
was detected at day 6 when B cells were treated with HIVNL4-3 but
not when treated with LPS/IL-4 (Figure 1B). It was interesting to
note that CD40L/IL-4 induced a slight proliferation even non
significant of B-cell in comparison to NT condition (6.0661.90%
and 3.2561.00% respectively) that could be considered as residual
loss of CFSE. Summarizing, although LPS/IL-4 and CD40L/IL-4
treatments caused a better B cells survival in comparison with non-
treated cells, B cells did not show a proliferation profile suggesting
that survival signal pathways initiated by HIVNL4-3 or LPS/IL-4
could be independent.
B Cells Activation
We researched whether the increased survival ability was
associated with the cellular activation. We compared the
expression of B cells surface activation markers CD69 and
CD71 by flow cytometry. B cells treated with HIVNL4-3 exhibited
higher expression of CD69 and CD71 very early after activation at
24 h post-culture (Figure 2A) (83.8262.90% and 49.1666.38% of
positive cells for 125 ng of p24gag, Table S1, Figure 2B) that was
significantly different in comparison with non-treated B cells
(42.4463.50% of positive cells for CD69 and 9.5760.84%
positive cells for CD71, Figure 2B; Table S1). After 4 days of
treatment, expression level of CD69 and CD71 were still
significantly higher when B cells were treated with HIVNL4-3
when compared with non-treated or in mock treated cells
(Figure 2B; Table 1).
To confirm that B cells activation was due to direct HIV
particles contact with B cells, we treated virus stock with different
concentration of anti-HIV neutralizing serum for 1 h before B
cells treatment. HIVNL4-3 treatment with anti-HIV serum
permitted to partially reverse B cells activation induced by non-
treated HIVNL4-3 particles (Figure 2C). With the higher anti-HIV
concentration serum, we reached around 30% of significant
reversion for CD69 marker expression and more than 58% of
reversion for CD71 marker expression (Figure 2C). Summing up,
our data indicate that HIVNL4-3 have the ability to induce cellular
activation detected by the increase of markers CD69 and CD71
expression at the surface of primary B cells in vitro. Moreover, this
activation is restricted to HIVNL4-3 treatment for CD71 activation
marker and restricted to HIVNL4-3, LPS/IL-4 and CD40L/IL-4
for CD69 marker suggesting that LPS/IL-4, CD40L/IL-4 or
HIV-derived cellular activation could act through independent
pathways.
B Cells Phenotype Dysregulation in vitro
We determined whether the HIVNL4-3 or other stimuli could
influence phenotype apart from activation markers at the surface
of the B cells. We compared the expression of B cells surface
Figure 1. B cells survival and proliferation. B cells survival (A) and
proliferation (B) were followed in vitro. (A) B cells were non-treated (NT)
or treated with HIVNL4-3 at 25 ng or 125 ng of p24
gag, with 125 ng of
p24gag boiled HIVNL4-3, with CD40L/IL-4or with LPS/IL-4. After 1, 4 and 6
days of culture, cells were collected and labeled with 7AAD, % of living
cells were quantified in 7AAD negative population and % of cell survival
was calculated as = (treated living cells / NT living cell at day 1 *100).
(+SD; * = p,0.05 for both HIV-treatment conditions, LPS/IL-4 and
CD40L/IL-4 conditions in comparison to NT condition)(B) After 1, 3 or
6 days post-treatment, percentage of proliferation was detected in
CFSE-labeled B cells as the percent of B cells that lost their CFSE staining
(See Figure S2). (+SD; * = p,0.05 for both HIV-treatment conditions in
comparison to NT condition). Mean of 7 experiments (125ng of p24gag,
125ng of p24gag boiled HIVNL4-3 or LPS/IL-4 condition), of 5 experiments
(CD40L/IL-4 condition) or 12 experiments (NT or 25 ng of p24gag
conditions) shown.
doi:10.1371/journal.pone.0039472.g001
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markers CD21hi, CD10, CD27 and CD20 (as described in Figure
S3) or of differentiation markers CD24hi or CD38hi after
treatments. B cells treated with 125 ng of p24gag HIVNL4-3
showed significant changes in immature subpopulation at 24 h of
treatment (Table S1). Significant changes were detected essentially
after 4 days of culture. Immature and naı¨ve mature B-cell
subpopulations were increased after 4 days of HIVNL4-3 treatment,
while activated mature, resting memory and exhausted tissue like
memory subpopulations showed a significant decrease in compar-
ison with non-treated B cells (Table 1).
Because phenotype reversion from more differentiated B cells
such as exhausted tissue like memory B cells through less
differentiated B cells such as immature and naı¨ve mature cells
were surprising, we checked the percentage of each markers
expression at the surface of B cells. At 4 days post-treatment,
expression of CD21hi was significantly higher when cells were
treated with 125 ng of p24gag of HIVNL4-3 in comparison with
non-treated cells or mock condition (73.5865.99%, 46.4364.31%
and 61.3867.00%, respectively). Moreover, CD27+ populations
were decreased after 4 days of treatment (9.8563.24% for the
Figure 2. Expression of activation markers on B cells. (A) Histogram plots of CD71 (left panel) and CD69 (right panel) expression markers at the
surface of B-cell. (B) B cells were NT or treated with 25 ng and 125 ng of p24gag of HIVNL4-3, with 125 ng of p24
gag of boiled-HIVNL4-3, with LPS/IL-4,
mock-treated or treated with CD40L/IL-4. At day 1 (grey bars) or day 4 (black bars) post-treatment, CD71 and CD69 surface markers were followed by
flow cytometry. Mean of 7 individuals donors excepted for mock and CD40L/IL-4 conditions (3 individuals donors) (+SD; * = p,0.05 in comparison to
NT for day 1 or 4 post-treatment). Mock corresponded to the supernatant of MT2 non-infected cells. (C) B cells were NT or treated with 125 ng of
p24gag of HIVNL4-3, with 125 ng of p24
gag of HIVNL4-3 treated with anti-HIV serum (Vol/Vol), mock-treated/anti-HIV serum or treated with LPS/IL-4. At
day 1 post-treatment percentage of CD71 and CD69 were followed by flow cytometry. Mean of 3 individuals donors is represented (6 SD;
* = p,0.05).
doi:10.1371/journal.pone.0039472.g002
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condition 125 ng of p24gag of HIVNL4-3, 39.9163.81% for NT
cells and 35.6465.46% for the mock condition; Table 1). Finally,
after 4 days of treatment, expression of the differentiation marker
CD24hi was significantly lower when B cells were treated with
125 ng of p24gag of HIVNL4-3 in comparison to non-treated or to
the mock conditions (8.9661.31%, 22.4161.16% and
21.0563.06% of positive cells, respectively; Table 1).
Summing up, we observed that the size of each B-cell
subpopulations was modified when cells were subjected to
HIVNL4-3 after 24 h or more deeply after 4 days of treatment.
These B-cell subpopulation categories were directed from a major
presence of less differentiated B cells subpopulations and minor
end-differentiated B-cell populations. These unexpected results
seemed to be essentially due to the increased presence of CD21hi
and CD10 and loss of CD27 markers when B cells were treated
with HIVNL4-3.
AID Expression Dysregulation in in vitro B Cells Culture
Given that activation of B cells is a normal process during
pathogens infection and that activation precedes CSR and SHM
processes induced by AID over-expression, we determined AID
mRNA expression in B cells cultured in vitro by real-time PCR.
mRNA from primary B cells cultured in vitro were extracted at
24 h after B cells treatment and only mRNAs showing a poor
degradation profile were subjected to real-time PCR and AID
mRNA expression levels were quantified. As shown in Figure 3A,
HIVNL4-3 induced AID mRNA up-regulation after 24 h of
treatment, B cells expressed an average of 10 times fold more
AID mRNA than non-treated B cells (Figure 3A). Lack of mRNA
AID induction in B cells when cells were treated with boiled-
HIVNL4-3 showed that a full integrity of the virus particles was
necessary to induce AID mRNA expression. Summing up, B cells
showed an increased expression of AID mRNA that was
comparable to LPS/IL-4 treatment very quickly after treatment
with HIVNL4-3 particles.
AID and CSR in in vitro B Cells Culture
We researched whether the increased AID mRNA expression
level was associated with CSR and with the production of Igs in
culture supernatant. Thus, we quantified IgG, IgA and IgE in the
supernatant of the B cells culture after 5 days or treatment. IgG
was detected on 10/10 of experiments and a slight non-significant
increase was detected on supernatant of B cells culture when B
cells were treated with 25 ng of p24gag of HIVNL4-3 (Figure 3B).
IgA was detected only in 2/10 experiments with a low level of IgA
production (Figure 3C). On both positive experiments, only one
showed increased level of IgA when cells were treated with
HIVNL4-3 in comparison to non-treated condition. However, IgA
level was increased in the same 2 experiments when cells were
treated with LPS/IL-4. Finally, IgE was detected only in 4/10
experiments although with very low level of detection, less than
3 ng/ml (Figure 3D). Interestingly, on 4 experiments 2 showed
undetectable level of IgE for non-treated condition, but exhibited
positive level when treated with HIVNL4-3 (Figure 3D). Due to the
low level of IgA and IgE detected in cell culture’s supernatant and
because 5 days of incubation could be considered too short to
induce detectable level of Igs in the supernatant of culture, we
decided to label intracellularly treated B cells with CD19, IgM,
IgD, IgA, IgE and IgG. Because great majority of changes for IgD
and IgM expression levels were observed at the MFI level, we
decided to quantify the integrated MFI that permitted us to
analyze changes on percentage of positive cells for the studied
marker and its MFI (iMFI=% of positive cells *MFI). Total IgM
or IgD levels in CD19+ B cells treated with HIVNL4-3 were not
significantly different in comparison with non-treated or mock
conditions (Figure 4A). Only LPS/IL-4 and CD40L/IL-4
treatment induced significant changes for IgM expression level
but not for the IgD expression level (Figure 4A). Figure S4 showed
histogram plots of 2 representative donors for intracellular IgG,
IgA and IgE markers. LPS/IL-4 treatment of B cells induced a
significant change in CD19+/IgA, IgG and IgE expression levels
Table 1. B-cell subpopulations after 4d of HIVNL4-3 treatment.
Percentage of B-cell populations after 4 days of contact with HIVNL4-3
B-cell populations NT 125 ng-HIV Mock SN boiled-HIV LPS/IL-4 CD40L/IL-4
Multiple labelling
Immature 2.68d (60.67) 16.06*a (63.58) 2.23a (60.40) 3.84a (61.35) 2.66a (61.03) 2.27a (60.79)
Naive mature 16.53d (62.95) 42.08*a (65.85) 31.29a (65.91) 20.87a (64.29) 10.11a (63.75) 13.83a (62.05)
Activated mature 13.28d (60.60) 1.59*a (60.65) 9.05a (61.73) 7.93a (61.14) 18.01a (62.36) 17.35a (61.24)
Resting memory 19.89d (62.48) 4.32*a (61.06) 22.14a (64.76) 25.28a (65.31) 19.28a (64.51) 19.32a (63.24)
Exhausted tissue like memory 28.98d (63.12) 13.46*a (63.04) 24.06a (63.59) 19.99a (63.97) 23.96a (63.01) 30.18a (61.82)
Plasmablast 0.65d (60.21) 0.33a (60.14) 1.35a (60.95) 0.36a (60.14) 0.80a (60.22) 1.11a (60.33)
Single labeling
CD27+ 39.91f (63.81) 9.85*f (63.24) 35.64a (65.46) 39.17b (66.83) 32.83d (66.42) 44.57a (66.95)
CD21hi 46.43e (64.31) 73.58*e (65.99) 61.38a (67.00) 61.21a (68.46) 37.28b (66.57) 40.58a (64.11)
CD10+ 16.22e (62.28) 22.90e (64.17) 8.58a (62.13) 15.82a (63.35) 19.21b (64.27) 14.60a (61.93)
CD71+ 7.44f (61.67) 56.12*f (63.89) 6.63a (61.69) 12.48a (64.58) 8.44c (62.09) 10.54a (61.66)
CD69+ 27.93f (64.31) 93.65*f (62.00) 18.44a (61.91) 26.27a (65.85) 80.71*c (66.98) 90.35*a (64.85)
CD24hi 22.41a (61.16) 8.96*a (61.31) 21.05a (63.06) ND ND 18.44a (63.25)
CD38hi 5.56a (60.56) 19.19a (69.18) 25.19*a (63.88) ND ND 9.38a (62.53)
Expression of cell surface markers and B-cell subpopulations size on B cells at 4 days post-treatment. Average percentage of cell surface markers and B-cell
subpopulations size on NT B cells or treated with 125 ng of p24gag of HIVNL4-3, Mock, boiled-HIVNL4-3, LPS/IL-4 and CD40L/IL-4 after 4 days of treatment. Results obtained
from at least 4(a), 6 (b), 7 (c), 8 (d), 10 (e), and 12 (f) individual donors (6SEM). NT for non-treated B cells, ND for Non-Determined (*; p,0.05 in comparison to NT).
doi:10.1371/journal.pone.0039472.t001
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in comparison to mock treated cells (Figure 4B). As previously
described, CD40L/IL-4 treatment was inducing significant
changes in CD19+/IgG and IgA expression level in comparison
to non-treated or mock conditions (Figure 4B, Figure S4A-B)
[30,31]. Finally, B cells treatment with HIVNL4-3 induced only the
significant increase of the IgE+ in CD19+ B cells (9.7461.89% in
comparison to non-treated condition that showed 2.9160.18% of
CD19+/IgE+, Figure S4C and Figure 4B). Summing up, HIVNL4-
3 treatment seemed to be able to induce significant IgE expression
whereas CD40L/IL-4 or LPS/IL-4 treatment induced significant
increased production of IgG or IgA.
Discussion
The objective of this study was to determine if HIV-1 particle by
itself could affect key properties of human primary B cells.
Summing up, we have found that these functional features of
human primary B cells in vitro were adversely affected by the direct
interaction with HIVNL4-3 particles.
Since several publications have shown that functional human
surface markers CD40L could be found at the surface of the HIV-
1, incorporated into HIV-1’s envelope membrane upon viral
budding from infected cells [27], we determined presence of
CD40L on virus producing cells and conclude that our HIVNL4-3
particles could not bear CD40L at their surface. Moreover, using
as control HIVNL4-3 particles treated with a neutralizing serum
anti-HIV-1 that blocked HIV-1 epitopes, we can assume that
HIV-1 particles could directly activate B cells in vitro and be
responsible for the increase of AID mRNA expression. As a
consequence, our results of B cells dysregulation could not be
explained by the presence of CD40L that is in contradiction with
some articles that shown that B-cell activation is essentially due to
the presence of CD40L at the surface of HIV-1 particles [26,28].
Regarding our results we proposed that B cells could be activated,
could express AID mRNA and could induce CSR in some extend
independently of the CD40L/CD40 activation pathway. In B-
cell/HIV-1 literature, some viral proteins were found to be bound
to DC-SIGN, to CD21 or to mannose C-type lectin receptors thus
our results showing importance of a native form of HIV-1 particles
and its proteins could be explained by the necessity of viral
particles to bound one or various cellular markers. However, we
cannot rule out the possibility that other cellular factors present at
the surface of HIV-1 particles could play a role in B-cell activation.
Further experiments would be necessary to determine, which viral
or cellular proteins are necessary for this strong B-cell activation
described in this work.
We assume that results of activation, proliferation and
differentiation found in this work could be associated to the non-
antigenic stimulation of B cell regardless lymphocyte interaction as
already determined in vitro [32,33,34]. In our study and in addition
of rapid B cells activation and cellular proliferation, HIV-1
particles induced a dysregulation of B-cell phenotype such as lost
of memory (CD27+) B cells. The loss of CD27 in B cells could
Figure 3. AID mRNA expression in B cells and Igs production. (A)AID mRNA expression was quantified at 24 h post treatment in B cells. NT or
treated B cells were cultured in vitro and mRNA was extracted and AID mRNA expression was quantified by real-time PCR. Fold increase was
calculated as ratio of AID mRNA expression in comparison to NT condition. Each grey dot represents one experiment. Black bar represent average
fold increase. (* = p,0.05). IgG (B), IgA (C) and IgE (D) production were quantified in cell culture supernatant by ELISA kit. (B) Mean of 10 experiments
was represented (+SD). (C, D) Only experiments with detectable level of IgA or IgE was shown where each bar represent the result obtained for one
individual donor. (ND: not determined).
doi:10.1371/journal.pone.0039472.g003
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explain previous results showing a loss of CD27+ memory B cells
and a major presence of CD27- (naive) B cells in HIV-1-infected
patients [14,35,36,37]. Moreover, recent article showed that
CD27 surface marker used to differentiate naı¨ve from memory
B cells should be challenged since CD27– B cells from seropositive
patients could produced class switched and somatically hyper-
mutated antibodies during chronic infection [38]. Such type of
results was determined in other chronic infection such as hepatitis
C virus (HCV) where CD27- B cells population was found
increased in peripheral blood of persistently infected patient and
where loss of memory B cells subset was due to a downregulation
of CD27 expression and not to cell death [37]. Consequently,
further experiments should be done in the aim to detect if the loss
of some B cells subpopulations is due to the decrease of surface
markers or due to selective B-cell subpopulations proliferation
versus B-cell death.
Finally, in addition to rapid phenotypic alterations of B-cell
subsets, increased expression of mRNA AID in B cells was indeed
followed by subsequent CSR process through expression of IgG,
IgE and IgA depending on the stimulation factor. It is important to
note that IgE expression upon HIV-1 stimulation was observed
when cells were labeled intracellularly and detected in B cells
culture supernatants. Importance of these results could be related
to the fact that unspecific IgE and IgG production were found in
HIV-1 patient developing hyper-immunoglobulinemia E and G,
autoimmune diseases and hypersensitivity observed in some HIV-
1 patients [6,8,39]. Such patients are then unable to respond
correctly to subsequent infections by facilitating the T cell
depletion and by the production of autoreactive antibodies. Thus,
our model could be essential to study mechanisms of the loss of
specific humoral immunity in HIV+ patients independently of
CD4+ T cells. Generally, B cells activation related to IgM, IgD or
IgG production dictate the extent and efficacy of the antibody
response, requiring a multitude of signals, including B-cell receptor
activation, CD40 stimulation, and cytokines signals to initiate
activation, differentiation, and proliferation. In our study, free of T
cells and free of CD40L context, HIV-1 treatment of B-cell could
induce cellular activation, proliferation and loss of principal
markers of B cells differentiation. We postulate that events
described in this work could participate at some extent to the
general immune system dysfunction associated with HIV-1
infection. Moreover, the induction of non-antigenic CSR could
suggest a limited ability for the host to induce a strong and specific
B-cell response to both HIV-1 and other opportunistic pathogens.
These findings should be taken in consideration during develop-
ment of therapeutic HIV vaccines because of the large level of B-
cell dysregulation.
Materials and Methods
B Cell Isolation from PBMC
Peripheral blood mononuclear cells (PBMC) were isolated on a
Ficoll-Hypaque density gradient (Rafer, Zaragoza, Spain) from
buffy coat obtained from transfusion centers of Albacete and
Madrid following national guidelines following the current
procedures of Spanish HIV BioBank [40]. B cells were purified
using the CD19 MicroBeads (Miltenyi, Bergisch Gladbach,
Germany), and contamination by other cell types was less than
3% (data not shown). Isolated B cells were cultured with RPMI
1640 medium (Biochrome, Berlin, Germany) supplemented with
5% heat-inactivated FCS, and antibiotics mix (125 mg/mL
ampicilin, 125 mg/mL cloxaciclin and 40 mg/mL gentamicin;
Sigma, St-Louis, MO, USA).
Virus Stock Production
Virus stock HIVNL4-3 was produced by infection of MT2 cells
(AIDS Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH: MT-2 from Dr. Douglas Richman [41]) with
NL4-3 virus stock coming from previous transient transfection of
pNL4-3 in 293T cells (ATCC, [42]). We produced parental X4
tropic HIVNL4-3 that encodes all known HIV-1 proteins [43] and
physical titers were evaluated by quantification of HIV-1 p24gag by
ELISA kit (Innogenetics, Gent, Belgium). Boiled virus was
produced by heating HIVNL4-3 at 96uC for 10 min to obtain our
negative control of activation as denaturated HIV-derived
antigens.
Culture and B Cells Treatment
B cells were treated with different amount of p24gag of infectious
HIVNL4-3 (25 ng or 125 ng of p24
gag/ 106 B cells). Cells were as well
treated with 20 mg/mL of Lipopolysaccharide (LPS) (Sigma-
Aldrich) and 20 ng/mL of interleukine 4 (IL-4) (Immunotools,
Figure 4. Class switch detected by intracellular labeling in in
vitro B cells. (A) NT or treated B cells were cultured during 5 days.
Intracellular CD19, IgM, IgD (A), IgG, IgA or IgE (B) markers were
followed by flow cytometry. (A) IgD and IgM expression levels were
followed in CD19+ population by percentage of positive cells for these
markers *MFI of the same both markers ( = iMFI; integrated MFI). Mean
of 5 individual donors (+SEM; * = p,0.05). (B) IgG, IgA and IgE
expression levels were followed in CD19+ population by percentage
of positive cells for each marker. Mean of 5 individual donors for IgG
and IgA and 3 individual donors for IgE (+SEM; * = p,0.05).
doi:10.1371/journal.pone.0039472.g004
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Friesoythe, Germany) or with 200 ng/ml of CD40L (eBioscience,
San Diego, CA, US) and 10 ng/ml of IL-4 as positive controls of
activation. Mock condition was defined by the use of non-infected
MT2 cells supernatant. Blocking experiments were performed
incubating 1/10, 1/20 and 1/50 (vol:vol) of HIVNL4-3 for 1 hour at
37uC before B cell treatment with anti-HIV neutralizing serum
(AIDS Research and Reference Reagent Program: HIV-1 Neutral-
izing Serum (specify 1 or 2) from Dr. Luba Vujcic [44]). This serum
was tested to neutralize several HIV-1 strains (see aidsreagent.org/
reagentdetail.cfm?t = polyclonal_antibodies&id = 87). B cells sur-
vival was followed by flow cytometry using 0.5 mg/ml of 7-animo-
actinomycin D (7AAD, Sigma-Aldrich) and B cells proliferation was
followed by flow cytometry using 1 mM of carboxyfluorescein
diacetate succinimidyl ester (CFSE) fromCellTrace CFSE cell prolif
kit (Invitrogen, Barcelona, Spain).
Flow Cytometry for B Cells Purity and Phenotype
B cells were analyzed by flow cytometry analysis. Cells were
stained for verification of B cells isolation purity along with
activation and differentiation markers, with fluorescein (FITC)-
labeled monoclonal Abs (MAbs): anti-CD21, anti-CD71, anti-
IgD (Beckman Coulter) and anti-IgE (Thermo Scientific,
Rockfold, IL, US). Phycoerythrin (PE)-labeled MAbs: anti-
CD3, anti-CD10, anti-CD27, anti-CD38, anti-CD40L (Beckman
Coulter) and anti-IgG (Miltenyi). R phycoerythrin-Texas-Red
(named ECD)-labeled MAbs: anti-CD19 and streptavidin-ECD
(Beckman Coulter). Biotin-conjugated anti-IgM (Beckman Coul-
ter) this antibody was revealed by steptavidin-PC7 (Beckman
Coulter). Phycoerythrin-Cyanin 5.1 (PC5)-labeled MAbs: anti-
CD16, anti-CD27, anti-CD24 and anti-CD69 (Beckman Coul-
ter) and anti-IgA (Jackson ImmunoResearch, Newmarket, UK).
Phycoerythrin-Cyanin 7 (PC7)-labeled MAbs: anti-CD14 and
anti-CD20 (Beckman Coulter). Intracellular anti-immunoglobu-
lin labeling was performed with Citofix/Cytoperm kit (BD
Biosciences, Franklin Lake, NJ, US) following manufacturer
instructions. Cells were then fixed by adding 2% formaldehyde
(Sigma-Aldrich) and analyzed by flow cytometry using a Gallios
cytometer and data was analyzed using FlowJo 7.6.1 software
(Ashland, OR, USA).
RNA Isolation, AID mRNA Quantification by Real-time
Polymerase Chain Reaction (Q-PCR)
RNA was extracted from 26106 cells with the Qiagen RNeasy
Plus mini kit (Qiagen, Germantown, USA). RNA integrity was
analyzed with Agilent 2100 bioanalyzer (Agilent Technologies,
Waldbronn, Germany) using RNA Nano chips (Agilent Technol-
ogies). 100 ng of RNA was reverse transcribed to make cDNA
(20 ml total volume) with the GoScript Reverse Transcription
System (Promega, Madison, WI, USA). cDNA was used in the Q-
PCR reaction with Brilliant II SYBR Green QPCR Master Mix
(Agilent Technologies, Waldbronn, Germany). The Q-PCR
reaction conditions were: 95uC 30 s, 60uC 1 min, 72uC 1 min
for 40 cycles. The primers used to amplify mRNA of AID were:
Forward Fw-59-CGCGCCGGGGTGCAAATAGCCATC-39,
and Reverse Rv-59-ACAGGGGCAAAAGGAT GCGCC-39,
and the primers to amplify mRNA of housekeepings were:
Fw(YWHAZ)-59-ACTTTTGGTACATTGTGGCTTCAA-39,
Rv(YWHAZ)-59-CCGCCAGGACAAACCAGT AT-39,
Fw(b2M)-59-TGCTGTCTCCATGTTTGATGTATCT-39 and
Rv(b2M)-59-TCTCTGCTCCCCACCTCTAAGT-39. AID
mRNA levels detected by Q-PCR were normalized with YWHAZ
and b2M, fold change was calculated following the 22DDCt
equation.
Measurement of Igs in Cells Culture Supernatant
Total IgG, IgE and IgA in culture supernatants were measured
using a human IgG, IgE and IgA enzyme-linked immunosorbent
assay (ELISA) quantitation kit (Innovative Research, peary Court
Novi, Mi, USA), according to the manufacturer’s specifications.
Plates were read immediately at 450 nm with Synergy 4 reader
(Biotek, Bad Friedrichshall, Germany).
Statistical Analysis
The comparison between the surface marker levels and B cell
subpopulations between non-treated B cells and treated B cells
treated was realized using the non-parametric Mann-Whitney test,
because the number of donors was low. All analyses were
performed using SPSS 17.0 Inc. (IBM, Chicago, Illinois, USA).
Supporting Information
Figure S1 CD40L expression on MT2 cell line. CD40L
expression was quantified by flow cytometry in activated PBMC
and MT2 cells. One of 2 representative experiments is shown.
Numbers were the percentage of cells positive in each quadrant.
(TIF)
Figure S2 B cell survival and proliferation gating. CFSE-
labeled B cells were treated for 6 days with 25 ng of p24gag HIV,
CD40L/IL-4 or NT. Cells were then labeled with 7AAD and fixed
before flow cytometry analysis. Gate and number into the upper
panels represent percentage of living cells (L). Cells gated in L were
analyzed for CFSE presence (lower panel). Proliferating cells were
cells that lost CFSE labeling. (Histogram dark grey: NT condition;
light grey: HIV-treatment condition and very light grey: CD40L/
IL-4 treated B cells).
(TIF)
Figure S3 B cells subpopulations. Subpopulations of B cells
were determined by combination of CD21, CD10, CD27 and
CD20 surface markers. CD21 low (gate A) and CD21 high (gate B)
populations were fist determined. CD21high and CD21low were
gated for CD10, CD27 and CD20. Thus, immature B cells
(CD21hiCD10+CD272, gate C), naı¨ve mature (CD21hiCD10-
CD272, gate D), resting memory (CD21hiCD10-CD27+, gate E),
activated mature (CD21loCD10-CD27+, gate F), long live plasma
cells (CD21loCD10-CD27+CD202, gate G) and exhausted tissue
like memory (CD21loCD10-CD27-CD20+, gate H) subpopula-
tions were detected and quantified by flow cytometry.
(TIF)
Figure S4 Intracellular Igs labeling in B cells. Two
individual donors on 5 were represented for intracellular labeling
of IgG (A), IgA (B) or IgE (C) after 5 days of treatment. Cells were
first gated on CD19+ population.
(TIF)
Table S1 Expression of cell surface markers and B-cell
subpopulations size on B cells at 24 h post-treatment.
Average percentage of cell surface markers and B-cell subpopu-
lations size on NT B cells or treated with 25 ng or 125 ng of
p24gag of HIVNL4-3, boiled-HIVNL4-3, and LPS/IL-4 after 24 h of
treatment. Results obtained from at least 6(a), 7 (b) and 10 (c)
individual donors (6SEM). NT for non-treated B cells (*; p,0.05
in comparison to NT).
(TIF)
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